Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 6/20 | 0.69 |
| ▸ | CASP1 | P29466 | 5/20 | 0.69 |
| ▸ | CASP7 | P55210 | 4/20 | 0.69 |
| ▸ | CASP9 | P55211 | 3/20 | 0.60 |
| ▸ | CASP4 | P49662 | 1/20 | 0.60 |
| ▸ | CASP5 | P51878 | 1/20 | 0.60 |
| ▸ | CASP6 | P55212 | 1/20 | 0.60 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.60 |
| ▸ | CASP10 | Q92851 | 1/20 | 0.60 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.56 |
| ▸ | NMBR | P28336 | 2/20 | 0.54 |
| ▸ | REN | P00797 | 2/20 | 0.54 |
| ▸ | CTSB | P07858 | 2/20 | 0.52 |
| ▸ | CTSK | P43235 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | IL1RN | P18510 | 1/20 | 0.49 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.49 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3725735 | 0.85 | CASP3 (0.62) | CASP3CASP1CASP7CASP9CASP4 | |
| SCHEMBL15462653 | 0.85 | CASP3 (0.92) | CASP3CASP1CASP7CASP9CASP4 | |
| SCHEMBL15455969 | 0.83 | CASP3 (0.63) | CASP3CASP1CASP7CASP9CASP4 | |
| SCHEMBL12829768 | 0.82 | CASP3 (1.00) | CASP3CASP1CASP7CASP9CASP4 | |
| SCHEMBL20609292 | 0.82 | CASP3 (1.00) | CASP3CASP1CASP7CASP9CASP4 | |
| SCHEMBL1396554 | 0.81 | CASP3 (0.60) | CASP3CASP1CASP7CASP9CASP4 | |
| SCHEMBL19015785 | 0.80 | CASP3 (0.81) | CASP3CASP1CASP7CASP9CASP4 | |
| SCHEMBL16376111 | 0.80 | CASP3 (0.92) | CASP3CASP1CASP7CASP9CASP4 | |
| SCHEMBL22346514 | 0.79 | NMBR (0.69) | CASP3CASP1CASP7CASP9CASP4 | |
| SCHEMBL22346513 | 0.79 | NMBR (0.69) | CASP3CASP1CASP7CASP9CASP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2697246-A1 | SELECTIVE CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | Novagenesis Foundation (CH) | 2014-02-19 | — | — | EP | claimed |
| US-20140038903-A1 | Selective Cysteine Protease Inhibitors and Uses Thereof | NEW WORLD LABORATORIES, INC. (CA) | 2014-02-06 | — | — | US | claimed |
| WO-2012140500-A9 | SELECTIVE CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES, INC. (CA) | 2013-10-24 | — | — | WO | claimed |
| WO-2012140500-A1 | SELECTIVE CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES, INC. (CA) | 2012-10-18 | — | — | WO | claimed |
| US-10975119-B2 | Selective cysteine protease inhibitors and uses thereof | GENESIS TECHNOLOGIES LIMITED (BB) | 2021-04-13 | — | — | US | disclosed |
| US-20180186833-A1 | SELECTIVE CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | GENESIS TECH LIMITED (BB) | 2018-07-05 | — | — | US | disclosed |
| US-9944674-B2 | Selective cysteine protease inhibitors and uses thereof | GENESIS TECHNOLOGIES LIMITED (BB) | 2018-04-17 | — | — | US | disclosed |
| EP-2697246-B1 | SELECTIVE CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | GENESIS TECH LIMITED (BB) | 2018-03-07 | — | — | EP | disclosed |
| EP-2697246-A1 | SELECTIVE CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | Novagenesis Foundation (CH) | 2014-02-19 | — | — | EP | disclosed |
| US-20140038903-A1 | Selective Cysteine Protease Inhibitors and Uses Thereof | NEW WORLD LABORATORIES, INC. (CA) | 2014-02-06 | — | — | US | disclosed |
| WO-2012140500-A9 | SELECTIVE CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES, INC. (CA) | 2013-10-24 | — | — | WO | disclosed |
| WO-2012140500-A1 | SELECTIVE CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES, INC. (CA) | 2012-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038903-A1 | Selective Cysteine Protease Inhibitors and Uses Thereof | SERPINB1, SERPINE1, CASP5 | CASP3 146/4885CASP1 25/4885CASP7 102/4885 |
| US-20180186833-A1 | SELECTIVE CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | SERPINB1, SERPINE1, CASP5 | CASP3 146/4885CASP1 25/4885CASP7 102/4885 |
| US-10975119-B2 | Selective cysteine protease inhibitors and uses thereof | SERPINB1, SERPINE1, CASP5 | CASP3 171/4885CASP1 29/4885CASP7 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.